Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citationDeveloping Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., & Chalasani, N. (2008) · Hepatology · doi:10.1002/hep.22272 · Cited by 389
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T. O., Joslyn, C., Kath, J. C., Niessen, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1582 · Cited by 359
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349
Chen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Covalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Guerciolini, R. (1997) · PubMed · Cited by 331
Activity-Based Profiling of Proteases
Sanman, L. E., & Bogyo, M. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035352 · Cited by 330
Flanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Idiosyncratic Adverse Drug Reactions: Current Concepts
Uetrecht, J., & Naisbitt, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007450 · Cited by 310
The pharmacological landscape and therapeutic potential of serine hydrolases
Bachovchin, D. A., & Cravatt, B. F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3620 · Cited by 308
Qiu, Y., Benet, L. Z., & Burlingame, A. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17940 · Cited by 298
Chemistry of Covalent Inhibition of the Gastric (H+, K+)-ATPase by Proton Pump Inhibitors
Shin, J. M., Cho, Y. M., & Sachs, G. (2004) · Journal of the American Chemical Society · doi:10.1021/ja049607w · Cited by 283
Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313733111 · Cited by 281
Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279
Iminoboronates: A New Strategy for Reversible Protein Modification
Cal, P. M. S. D., Vicente, J. B., Pires, E., Coelho, A. V., Veiros, L. F., Cordeiro, C., & Gois, P. M. P. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303436y · Cited by 275
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269
Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505194w · Cited by 260
Protein‐Reactive Natural Products
Drahl, C., Cravatt, B. F., & Sorensen, E. J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200500900 · Cited by 250
Yang, P.-Y., Liu, K., Ngai, M. H., Lear, M. J., Wenk, M. R., & Yao, S. Q. (2010) · Journal of the American Chemical Society · doi:10.1021/ja907716f · Cited by 229
Godin-Heymann, N., Ulkus, L., Brannigan, B. W., McDermott, U., Lamb, J., Maheswaran, S., Settleman, J., & Haber, D. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2387 · Cited by 203
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Drug discovery considerations in the development of covalent inhibitors
Mah, R., Thomas, J. R., & Shafer, C. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.003 · Cited by 193
Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 193
Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors
Miller, R. M., Paavilainen, V. O., Krishnan, S., Serafimova, I. M., & Taunton, J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja401221b · Cited by 191
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12279 · Cited by 187
Dahlin, D. C., & Nelson, S. D. (1982) · Journal of Medicinal Chemistry · doi:10.1021/jm00350a001 · Cited by 185
How Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182
Mass Spectrometry-Based Proteomics in Preclinical Drug Discovery
Schirle, M., Bantscheff, M., & Kuster, B. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.002 · Cited by 180
Targeted covalent drugs of the kinase family
Singh, J., Petter, R. C., & Kluge, A. F. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.168 · Cited by 177
Cee, V. J., Volak, L. P., Chen, Y., Bartberger, M. D., Tegley, C. M., Arvedson, T., McCarter, J. D., Tasker, A. S., & Fotsch, C. H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01018 · Cited by 172
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases
Kathman, S. G., Xu, Z., & Statsyuk, A. V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500345q · Cited by 170
Drug discovery for a new generation of covalent drugs
Kalgutkar, A. S., & Dalvie, D. K. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.688744 · Cited by 166
Jöst, C., Nitsche, C., Scholz, T., Roux, L., & Klein, C. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006918 · Cited by 162
Baillie, T. A. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060062o · Cited by 160
Self-citationOballa, R. M., Truchon, J., Bayly, C. I., Chauret, N., Day, S., Crane, S. N., & Berthelette, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.044 · Cited by 150
Scheers, E. M., Leclercq, L., de Jong, J., Bode, N., Bockx, M., Laenen, A., Cuyckens, F., Skee, D. M., Murphy, J., Sukbuntherng, J., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060061 · Cited by 148
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
Stopfer, P., Marzin, K., Narjes, H., Gansser, D., Shahidi, M., Uttereuther-Fischer, M., & Ebner, T. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1803-9 · Cited by 137
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 135
Böhme, A., Thaens, D., Paschke, A., & Schüürmann, G. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800492x · Cited by 125
Glutathione: a vehicle for the transport of chemically reactive metabolites in vivo
Baillie, T. A., & Slatter, J. G. (1991) · Accounts of Chemical Research · doi:10.1021/ar00009a003 · Cited by 120
Self-citationReversibility of Covalent Electrophile−Protein Adducts and Chemical Toxicity
Lin, D., Saleh, S., & Liebler, D. C. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800248x · Cited by 114
The Design of Covalent Allosteric Drugs
Nussinov, R., & Tsai, C.-J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124401 · Cited by 112
Shibata, Y., & Chiba, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061424 · Cited by 111
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 108
Hoffmann, K. J., Streeter, A. J., Axworthy, D. B., & Baillie, T. A. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12555-8 · Cited by 108
Self-citationGushwa, N. N., Kang, S., Chen, J., & Taunton, J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja310659j · Cited by 101
Berteotti, A., Vacondio, F., Lodola, A., Bassi, M., Silva, C., Mor, M., & Cavalli, A. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400489b · Cited by 101
Dansette, P. M., Libraire, J., Bertho, G., & Mansuy, D. (2009) · Chemical Research in Toxicology · doi:10.1021/tx8004828 · Cited by 97
Irreversible Nek2 Kinase Inhibitors with Cellular Activity
Henise, J., & Taunton, J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200222m · Cited by 96
Reversible Michael Additions: Covalent Inhibitors and Prodrugs
Johansson, M. H. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575112091330 · Cited by 96
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine
Hagel, M., Niu, D., St Martin, T., Sheets, M. P., Qiao, L., Bernard, H., Karp, R. M., Zhu, Z., Labenski, M. T., Chaturvedi, P., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.492 · Cited by 95
Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
Nacht, M., Qiao, L., Sheets, M. P., Martin, T. S., Labenski, M., Mazdiyasni, H., Karp, R., Zhu, Z., Chaturvedi, P., Bhavsar, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3008745 · Cited by 90
Electrophilic Warhead-Based Design of Compounds Preventing NLRP3 Inflammasome-Dependent Pyroptosis
Cocco, M., Garella, D., Stilo, A. D., Borretto, E., Stevanato, L., Giorgis, M., Marini, E., Fantozzi, R., Miglio, G., & Bertinaria, M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501072b · Cited by 89
Pérez, D. I., Palomo, V., Pérez, C., Gil, C., Dans, P. D., Luque, F. J., Conde, S., & Martínez, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1016279 · Cited by 80
Xia, G., Chen, W., Zhang, J., Shao, J., Zhang, Y., Huang, W., Zhang, L., Qi, W., Sun, X., Li, B., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5014659 · Cited by 80
Scientists in the dark after French clinical trial proves fatal
Butler, D., & Callaway, E. (2016) · Nature · doi:10.1038/nature.2016.19189 · Cited by 80
Activity-based protein profiling: an enabling technology in chemical biology research
Li, N., Overkleeft, H. S., & Florea, B. I. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.01.008 · Cited by 79
A simple in vitro assay for assessing the reactivity of nitrile containing compounds
MacFaul, P. A., Morley, A., & Crawford, J. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.105 · Cited by 77
Zapf, C. W., Gerstenberger, B. S., Li, X., Limburg, D. C., Anderson, D. R., Caspers, N. L., Han, S., AULABAUGH, A. E., Kurumbail, R. G., Shakya, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301190s · Cited by 76
Irreversible Protein Kinase Inhibitors
Garuti, L., Roberti, M., & Bottegoni, G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391705 · Cited by 76
Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology
Erve, J. C. L. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.923 · Cited by 76
Acylating drugs: redesigning natural covalent inhibitors
Kluge, A. F., & Petter, R. C. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.035 · Cited by 72
Dahal, U. P., Obach, R. S., & Gilbert, A. M. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400301q · Cited by 71
Docking-Based Virtual Screening of Covalently Binding Ligands: An Orthogonal Lead Discovery Approach
Schröder, J., Klinger, A., Oellien, F., Marhöfer, R. J., Duszenko, M., & Selzer, P. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3013932 · Cited by 66
Characterization of HKI-272 Covalent Binding to Human Serum Albumin
Wang, J., Li-Chan, X. X., Atherton, J., Deng, L., Espina, R. J., Yu, L., Horwatt, P., Ross, S. A., Lockhead, S., Ahmad, S. S., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032292 · Cited by 61
Are Chemically Reactive Metabolites Responsible for Adverse Reactions to Drugs?
Williams, D. P., Kitteringham, N. R., Naisbitt, D. J., Pirmohamed, M., Smith, D. A., & Park, B. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337423 · Cited by 58
Irreversible kinase inhibitors gain traction
Sanderson, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4103 · Cited by 55
Covalent modification as a strategy to block protein–protein interactions with small-molecule drugs
Way, J. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00049-6 · Cited by 55
Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer
Liu, F., Zhang, X., Weisberg, E., Chen, S., Hur, W., Wu, H., Zhao, Z., Wang, W., Mao, M., Cai, C., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4000629 · Cited by 55
Recent Advances in the Design of Cathepsin S Inhibitors
Wiener, J. J. M., Sun, S., & Thurmond, R. L. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791113432 · Cited by 53
Bruno, S., Pinto, A., Paredi, G., Tamborini, L., Micheli, C. D., Pietra, V. L., Marinelli, L., Novellino, E., Conti, P., & Mozzarelli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500747h · Cited by 53
Pharmacokinetics of oral neratinib during co‐administration of ketoconazole in healthy subjects
Abbas, R., Hug, B. A., Leister, C. A., Burns, J., & Sonnichsen, D. S. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03845.x · Cited by 52
Basu, D., Richters, A., & Rauh, D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.038 · Cited by 50
Targeted Covalent Enzyme Inhibitors
Noe, M. C., & Gilbert, A. M. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00027-8 · Cited by 49
Vroomen, L. H. M., Berghmans, M. C. J., Groten, J. P., Koeman, J. H., & van BLADEREN, P. J. (1988) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(88)80007-3 · Cited by 47
Carmi, C., Lodola, A., Rivara, S., Vacondio, F., Cavazzoni, A., Alfieri, R. R., Ardizzoni, A., Petronini, P. G., & Mor, M. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711797247725 · Cited by 46
Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine
Kwarcinski, F. E., Fox, C. C., Steffey, M. E., & Soellner, M. B. (2012) · ACS Chemical Biology · doi:10.1021/cb300337u · Cited by 46
Targeting Protein Kinases with Selective and Semipromiscuous Covalent Inhibitors
Miller, R. M., & Taunton, J. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-397918-6.00004-5 · Cited by 42
Reversible Covalent Binding of Neratinib to Human Serum Albumin In Vitro
Chandrasekaran, A., Shen, L., Lockhead, S., Oganesian, A., Wang, J., & Scatina, J. (2010) · Drug Metabolism Letters · doi:10.2174/187231210792928206 · Cited by 40
Irreversible inhibitors of the erbB family of protein tyrosine kinases
Denny, W. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00194-8 · Cited by 40
Morgen, M., Jöst, C., Malz, M., Janowski, R., Niessing, D., Klein, C. D. P., Gunkel, N., & Miller, A. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00755 · Cited by 38
Otrubova, K., Brown, M. A., McCormick, M. S., Han, G. W., O’Neal, S. T., Cravatt, B. F., Stevens, R. C., Lichtman, A. H., & Boger, D. L. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4014997 · Cited by 35
Identification of covalent active site inhibitors of dengue virus protease
Koh, X., Joy, J. K., Wang, S. F., Kwek, P. Z., Wee, J., Wan, K. F., Gayen, S., Chen, A., Kang, C., Lee, M. A., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s94207 · Cited by 34
DRAHL, C., Cravatt, B. F., & Sorensen, E. J. (2005) · Angewandte Chemie · doi:10.1002/ange.200500900 · Cited by 34
Otrubova, K., Cravatt, B. F., & Boger, D. L. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401820q · Cited by 33
Selective Inhibition of Mutant Ras Protein through Covalent Binding
Rudolph, J., & Stokoe, D. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400233 · Cited by 29
Reversible Covalent Inhibition of eEF-2K by Carbonitriles
Devkota, A. K., Edupuganti, R., Yan, C., Shi, Y., Jose, J., Wang, Q., Kaoud, T. S., Cho, E. J., Ren, P.-Y. Y., & Dalby, K. (2014) · ChemBioChem · doi:10.1002/cbic.201402321 · Cited by 29
Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents
Omar, A. M., Mahran, M. A., Ghatge, M. S., Chowdhury, N., Bamane, F. H., El‐Araby, M. E., Abdulmalik, O. Y., & Safo, M. K. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00367a · Cited by 22
Gersch, M., Hackl, M. W., Dubiella, C., Dobrinevski, A., Groll, M., & Sieber, S. A. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.01.004 · Cited by 21
Dickson, H. M., Wilbur, A., Reinke, A. A., Young, M. A., & Vojtek, A. B. (2015) · BMC Neuroscience · doi:10.1186/s12868-015-0171-5 · Cited by 20
A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Moghaddam, M. F., Tang, Y., O’Brien, Z., Richardson, S., Bacolod, M. D., Chaturedi, P., Apuy, J. L., & Kulkarni, A. A. (2014) · Drug Metabolism Letters · doi:10.2174/1872312808666140317151735 · Cited by 18
Yang, Y., Shu, Y.-Z., & Humphreys, W. G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00460 · Cited by 17
Šmelcerović, A., Miljković, F. N., Kolarević, A., Lazarević, J., Ɖorđević, A., Kocic, G. M., & Anderluh, M. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150619142731 · Cited by 16
Bruton's TK Inhibitors: Structural Insights and Evolution of Clinical Candidates
Xing, L., & Huang, A. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.24 · Cited by 14
Discovery of an irreversible HCV NS5B polymerase inhibitor
Zeng, Q., Nair, A. G., Rosenblum, S. B., Huang, H., Lesburg, C. A., Jiang, Y., Selyutin, O., Chan, T., Bennett, F., Chen, K. X., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.060 · Cited by 12
Ballard, T. E., Dahal, U. P., Bessire, A. J., Schneider, R. P., Geoghegan, K. F., & Vaz, A. D. N. (2015) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7375 · Cited by 11
Monks, T. J., & Lau, S. S. (2012) · Toxicologic Pathology · doi:10.1177/0192623312467399 · Cited by 8
The contributions of Sidney D. Nelson to drug metabolism research
Baillie, T. A. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.985790 · Cited by 7
Self-citationSelektive Inhibierung von mutiertem Ras‐Protein durch kovalent bindende Liganden
Rudolph, J., & Stokoe, D. (2014) · Angewandte Chemie · doi:10.1002/ange.201400233 · Cited by 6
Kalgutkar, A. S., Dalvie, D., Obach, R. S., & Smith, D. A. (2012) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527655748
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“565,567,573”
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
Douangamath, A., Fearon, D., Gehrtz, P., Krojer, T., Lukacik, P., Owen, C. D., Resnick, E., Strain-Damerell, C., Aimon, A., Ábrányi-Balogh, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18709-w · Cited by 526
Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
Eaton, J. K., Furst, L., Ruberto, R. A., Moosmayer, D., Hilpmann, A., Ryan, M. J., Zimmermann, K., Cai, L. L., Niehues, M., Badock, V., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0501-5 · Cited by 489
An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells
Vinogradova, E. V., Zhang, X., Remillard, D., Lazar, D. C., Suciu, R. M., Wang, Y., Bianco, G., Yamashita, Y., Crowley, V. M., Schafroth, M. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.001 · Cited by 351
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.